The Impact of Primary Hyperparathyroidism on the Oral Cavity

Padbury, Allan D.; Tözüm, Tolga F.; Taba, Mário; Ealba, Erin L.; West, Brady T.; Burney, Richard E.; Gauger, Paul G.; Giannobile, William V.; McCauley, Laurie K.

doi:10.1210/jc.2005-2282

Cited by 72 publications

(58 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ardine et al 71 reported that patients with bisphosphonate-associated ONJ had persistently higher PTH levels compared to controls without ONJ and they suggested that high PTH may be involved in the pathogenesis of ONJ. Evidence against this theory is that in patients with primary hyperparathyroidism and elevated PTH, lesions in the oral cavity include reduced radicular lamina dura, reduced interdental alveolar bone density and reduced cortical bone at the gonial index, 72 whereas the bisphosphonate-associated ONJ is characterized by osteopetrosis-like osseous sclerosis with thickening of the lamina dura and of the alveolar crest and sclerosis of the alveolar margin. 73 …”

Section: Osteonecrosis Of the Jawmentioning

confidence: 99%

Bisphosphonate-associated adverse events

Papapetrou

2009

258

174

View full text Add to dashboard Cite

The adverse events of the nitrogen-containing bisphosphonates are reviewed. Oral bisphosphonates (alendronate, risedronate and ibandronate), mainly used for the treatment of osteoporosis, have been associated with adverse events from the upper gastrointestinal tract, acute phase response, hypocalcaemia and secondary hyperparathyroidism, musculoskeletal pain, osteonecrosis of the jaw and ocular events. Intravenous bisphosphonates (pamidronate, ibandronate and zoledronic acid), used in oncology and for the treatment of osteoporosis, have been associated with all the above adverse events, except those from the upper gastrointestinal tract. Moreover, pamidronate and zoledronic acid have been associated with renal toxicity. Association of bisphosphonates with atrial fibrillation and atypical fractures of the femoral diaphysis remains uncertain. There are a few case reports relating bisphosphonates to cutaneous reactions, oral ulcerations, hepatitis and esophageal cancer. Generally, intravenous are more potent than oral bisphosphonates and the frequency and severity of some of the bisphosphonate-associated adverse events are dose and potency dependent.

show abstract

Section: Osteonecrosis Of the Jawmentioning

confidence: 99%

Bisphosphonate-associated adverse events

Papapetrou

2009

258

174

View full text Add to dashboard Cite

show abstract

“…Classic skeletal lesions, which are bone resorption, bone cysts, brown tumours and generalized osteopenia, occur in less than 5% of cases. [31] …”

Section: Metabolic Lesions Hyperparathyroidismmentioning

confidence: 99%

“…It may be seen in patients with either primary or secondary hyperparathyroidism. [31] www.wjpps.com [31]…”

Section: Clinical Featuresmentioning

confidence: 99%

Cell With a Giant Name:-Giant Cell Lesion of the Oral Cavity-an Update

Nazeer¹

2017

WJPPS

View full text Add to dashboard Cite

show abstract

“…However, several cases of brown tumor that did not disappear or even grew after normalization of HPT level have been reported. In these cases brown tumor resection should be the preferred treatment (8,9,(13)(14)(15).…”

Section: Oral Manifestations and Dental Management Of Patients With Pmentioning

confidence: 99%

Dental management of patients with endocrine disorders

Fabuel¹,

Soriano²,

Pérez³

2010

J Clin Exp Dent

View full text Add to dashboard Cite

Introduction: The endocrine system is responsible for hormonal secretion and is closely related to the central nervous system, as it diversifies its functions through the hypothalamus and pituitary glands. It controls physiological processes and maintains homeostasis. The neuroendocrine system is responsible for adaptation to environmental changes. Therefore, in dentistry, it is important to be aware of the risks and difficulties that may arise during the dental management of patients with endocrine disorders, and that visits to the dental clinics often represent a stressful situation. Objectives: To review the literature on oral manifestations and dental management in patients with endocrine disorders (disorders of the thyroid, parathyroid and adrenal glands). Material and Methods:For the literature review, we carried out a search in Pubmed / Medline database using limits and keywords according to the controlled vocabulary "Medical Subject Headings" (MeSH). We obtained a total of 19 articles (ten literature reviews, one case-control study, and eight clinical case series). Results and discussion: We describe the most common oral manifestations in patients with endocrine disorders and the special dental management that should be carried out on these patients.

show abstract

The Impact of Primary Hyperparathyroidism on the Oral Cavity

Cited by 72 publications

References 35 publications

Bisphosphonate-associated adverse events

Bisphosphonate-associated adverse events

Cell With a Giant Name:-Giant Cell Lesion of the Oral Cavity-an Update

Dental management of patients with endocrine disorders

Contact Info

Product

Resources

About